Experimental Drug Added to Standard Therapy Yields 19% Functional Cure Rate for Chronic HBV in Two Trials, Only in Already-Controlled Patients
A six-month course of an experimental drug combined with existing antivirals produced functional cures in 19 percent of participants whose chronic hepatitis B infections were already well controlled.
qz.comA six-month regimen of an experimental drug added to standard antivirals produced functional cures in 19 percent of participants across two efficacy trials for chronic hepatitis B virus infection. Functional cure in these trials meant patients could control the virus naturally without further treatment.
The participants entered the studies with infections already relatively well controlled by existing drugs.
@ScienceMagazine reported the findings from these two trials. The effectiveness of the experimental drug in populations whose infections are harder to manage remains unknown.
